Filtered By:
Drug: Metformin
This page shows you your search results in order of relevance. This is page number 20.
Order by Relevance | Date
Total 6513 results found since Jan 2013.
Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
Expert Rev Clin Pharmacol. 2021 Apr 22:1-16. doi: 10.1080/17512433.2021.1917374. Online ahead of print.ABSTRACTIntroduction: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are significant non-communicable diseases that often affect individuals concurrently. In individuals with both T2DM and NAFLD, there is evidence that anti-diabetic therapies may demonstrate potential combined beneficial metabolic and reduced hepatic inflammatory effects.Areas covered: A PubMed and Google Scholar search was performed to find relevant literature. Included studies focused on individuals with T2DM and NAFLD rece...
Source: Pharmacological Reviews - April 22, 2021 Category: Drugs & Pharmacology Authors: Elizabeth M Lamos Megan Kristan Maka Siamashvili Stephen N Davis Source Type: research
The effects of myo-inositol vs. metformin on the ovarian function in the polycystic ovary syndrome: a systematic review and meta-analysis
CONCLUSIONS: Due to the dearth of related research and the high heterogeneity of the Randomized Clinical Trials (RCTs) included in other studies, the present systematic review could not establish any differences between metformin and myo-inositol concerning the hormonal profile and the ovarian function. However, the findings indicated that myo-inositol could improve fertility outcomes by modulating hyperandrogenism. Randomized trials are required to understand the mechanistic actions of myo-inositol in comparison with those of metformin regarding oocyte and embryo quality, fertilization, pregnancy, and live birth rates.PMI...
Source: Pharmacological Reviews - April 20, 2021 Category: Drugs & Pharmacology Authors: M Azizi Kutenaei S Hosseini Teshnizi P Ghaemmaghami F Eini N Roozbeh Source Type: research
Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
Expert Rev Clin Pharmacol. 2021 Apr 22:1-16. doi: 10.1080/17512433.2021.1917374. Online ahead of print.ABSTRACTIntroduction: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are significant non-communicable diseases that often affect individuals concurrently. In individuals with both T2DM and NAFLD, there is evidence that anti-diabetic therapies may demonstrate potential combined beneficial metabolic and reduced hepatic inflammatory effects.Areas covered: A PubMed and Google Scholar search was performed to find relevant literature. Included studies focused on individuals with T2DM and NAFLD rece...
Source: Pharmacological Reviews - April 22, 2021 Category: Drugs & Pharmacology Authors: Elizabeth M Lamos Megan Kristan Maka Siamashvili Stephen N Davis Source Type: research
Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option
CONCLUSION: There are treatments available for antipsychotic-induced hyperprolactinemia in patients who are unable to alter their current antipsychotic regimen. However, there remains a need for additional short- and long-term studies to determine the efficacy and safety of these treatment strategies, given that patients taking antipsychotics typically require chronic, life-long treatment for their illnesses.PMID:33954421 | DOI:10.1093/ajhp/zxab065
Source: American Journal of Health-System Pharmacy : AJHP - May 6, 2021 Category: Drugs & Pharmacology Authors: Matthew M Rusgis Afaq Y Alabbasi Leigh Anne Nelson Source Type: research
The different hypoglycemic effects between East Asian and non-Asian type 2 diabetes patients when treated with SGLT-2 inhibitors as an add-on treatment for metformin: a systematic review and meta-analysis of randomized controlled trials
CONCLUSION: SGLT-2 inhibitors as an add-on treatment for metformin are more efficacious in East Asian T2DM patients than in non-Asian T2DM patients without an additional risk of severe adverse events.PMID:33973870 | DOI:10.18632/aging.202945
Source: Aging - May 11, 2021 Category: Biomedical Science Authors: Xianzhi Li Qianping Zhang Xiaojun Zhou Siyi Guo Shan Jiang Yuhan Zhang Ruzhen Zhang Jianjun Dong Lin Liao Source Type: research
The Genetics of Adverse Drug Outcomes in Type 2 Diabetes: A Systematic Review
Conclusion: In spite of limited studies investigating genetics and ADR in diabetes, some convincing results are emerging. Genetic variants in genes encoding drug transporters and metabolizing enzymes are implicated in metformin-related GI adverse effects, and sulfonylurea-induced hypoglycemia, respectively. Further studies to investigate newer antidiabetic drugs such as DPP-4i, GLP-1RA, and SGLT2i are warranted. In addition, pharmacogenetic studies that account for race and ethnic differences are required.
Source: Frontiers in Genetics - June 14, 2021 Category: Genetics & Stem Cells Source Type: research
The function of metformin in endometrial receptivity (ER) of patients with polycyclic ovary syndrome (PCOS): a systematic review and meta-analysis
CONCLUSION: Metformin may improve endometrial receptivity (ER) in PCOS patients by increasing EMT and reducing endometrial artery RI. However, the level of most original studies was low, with small sample sizes. More large-scale, long-term RCTs with rigorous methodologies are needed.PMID:34127011 | DOI:10.1186/s12958-021-00772-7
Source: Reproductive Biology - June 15, 2021 Category: Reproduction Medicine Authors: Lifang Yuan Hongbo Wu Weiyu Huang Yin Bi Aiping Qin Yihua Yang Source Type: research
A systematic review on outcome reporting in randomised controlled trials assessing treatment interventions in pregnant women with pregestational diabetes
CONCLUSIONS: Outcome reporting in treatment interventions trials of pregnant women with PGDM is varied, making it difficult to synthesize evidence especially for rare outcomes. Systems are needed to standardise outcome reporting in future clinical trials and thus facilitate evidence synthesis in this area of maternal diabetes.PMID:34258852 | DOI:10.1111/1471-0528.16842
Source: BJOG : An International Journal of Obstetrics and Gynaecology - July 14, 2021 Category: OBGYN Authors: Oratile Kgosidialwa Delia Bogdanet Aoife Egan Christine Newman Paula M O'Shea Linda Biesty Carmel McDonagh Christine O'Shea Declan Devane Fidelma Dunne INSPIRED group Source Type: research
Could the use of butyric acid have a positive effect on microbiota and treatment of type 2 diabetes?
CONCLUSIONS: T2DM is a widespread chronic disease. Understanding role of microbiota in type 2 diabetes and the mechanisms connecting T2DM and alterations in gut microbiota could be the key to improved treatment of T2DM.PMID:34286509 | DOI:10.26355/eurrev_202107_26250
Source: Pharmacological Reviews - July 21, 2021 Category: Drugs & Pharmacology Authors: E Stachowska M Wi śniewska A Dzie życ A Bohatyrewicz Source Type: research
Metformin and survival of women with breast cancer: A meta-analysis of randomized controlled trials
CONCLUSION: Current evidence from phase II clinical trials does not support that additional use of metformin could improve the survival outcome in women with breast cancer.PMID:34397110 | DOI:10.1111/jcpt.13500
Source: Clinical Breast Cancer - August 16, 2021 Category: Cancer & Oncology Authors: Qiandan Wang Xiufen Ma Jianping Long Xiaoyan Du Bin Pan Hongyan Mao Source Type: research
